XML 67 R39.htm IDEA: XBRL DOCUMENT v3.3.1.900
Description of Business and Basis of Presentation - Additional Information (Detail) - USD ($)
3 Months Ended 12 Months Ended
Jan. 04, 2016
Aug. 11, 2014
Sep. 30, 2014
Dec. 31, 2015
Dec. 31, 2014
Sep. 23, 2014
Dec. 31, 2013
Dec. 31, 2012
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Accumulated deficit       $ (2,863,229,000) $ (2,494,784,000)      
Cash and cash equivalents       59,074,000 $ 120,841,000   $ 70,790,000 $ 61,840,000
Amount available for future borrowings       $ 30,100,000        
License and Collaboration Agreement with Sanofi                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Up-front fee     $ 150,000,000          
Profits and losses sharing percentage   35.00%   35.00%        
Maximum secured loan facility           $ 175,000,000    
License and Collaboration Agreement with Sanofi | Sanofi-Aventis Deutschland GmbH                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Up-front fee       $ 150,000,000        
Profits and losses sharing percentage   65.00%   65.00%        
Maximum secured loan facility       $ 175,000,000        
Senior convertible notes due December 31, 2019 | Deerfield | Minimum | Facility Agreement | Less portion of commitment asset                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Available amount of credit facility under covenant restrictions       $ 25,000,000        
Subsequent Event | License and Collaboration Agreement with Sanofi                
Organization, Consolidation and Presentation of Financial Statements Disclosure [Line Items]                
Termination date Jul. 04, 2016